← Back to Clinical Trials
Recruiting NCT07252895

NCT07252895 EXOPULSE Suit and Walking Ability of Patients With Multiple Sclerosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07252895
Status Recruiting
Phase
Sponsor Otto Bock France SNC
Condition Multiple Sclerosis
Study Type INTERVENTIONAL
Enrollment 77 participants
Start Date 2026-03-30
Primary Completion 2027-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
EXOPULSE Suit in Active modeEXOPULSE Suit in Sham mode

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 77 participants in total. It began in 2026-03-30 with a primary completion date of 2027-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The EXOPULSE Suit is a medical device composed of 50 electrodes capable of stimulating up to 43 major muscle groups throughout the body. The multisite electrical stimulation relaxes tense and spastic muscles, thereby enhancing mobility and balance. This non-invasive body garment is intended for home use and should be used for 1 hour every other day. This research aims to confirm the benefits of the EXOPULSE Suit in individuals with Multiple Sclerosis, including improvements in walking ability.

Eligibility Criteria

Inclusion Criteria: * Person with a clear Multiple Sclerosis diagnosis according to the 2017 revision of the McDonald criteria since at least 3 months. * Person with an Expanded Disability Status Scale (EDSS) score ≥ 4 and ≤ 6 * Person with stable walking ability for at least two weeks prior to the inclusion visit (variation at the MSWS-12 questionnaire \< 8/100 points) * Person not treated with fampridine due to contra-indication or adverse events or not respondent or no longer respondent or reluctant to taking drugs * Person with spasticity at the lower limb(s), attested by a Modified Ashworth Scale ≥ 1+ of at least one of the following muscle groups: quadriceps, hamstrings, triceps surae, tibialis anterior * Person who never tried EXOPULSE SUIT Exclusion Criteria: * Person under 18 years old * Person having a contraindication to using EXOPULSE SUIT * Person using an electronic life-support equipment, e.g. pacemakers or hight-frequency surgical equipment and person using an ECG equipment * Person affected by other somatic or neuropsychiatric diagnoses (e.g., arrhythmias, uncontrolled epilepsy, diseases causing osteoarticular and muscular pain). * Person with relapses over the last 3 months before the inclusion * Person who had a modification of his/her medical treatments of the multiple sclerosis or related to motor performance over the last 3 months before the inclusion * Person who had a new medical treatment of the multiple sclerosis or related to motor performance over the last 3 months before the inclusion * Person who had an injection of botulinum toxin in at least one of the main muscle groups of the lower limbs over the last 4 months before the inclusion * Person planning to use a new medical device during the study (ex: ankle-foot orthosis…) * Person undergoing or planning to undergo an intensive rehabilitation phase * Person that is part of another study * Person who cannot be fitted with EXOPULSE SUIT due to inexistent Suitable size of the Suit (eg: BMI\>35; user height \< 100 cm or \> 205cm) * Person who does not have a smartphone or who cannot or does not want to use his/her smartphone for operating the EXOPULSE App * Person not available to undergo all medical visits during the study * Person unable to understand verbal and written instructions in french * Pregnant person * Persons under juridical protection * Prisoners

Contact & Investigator

Central Contact

Aurelie LACROIX, Ing.

✉ aurelie.lacroix@ottobock.com

📞 0033 (0)7 86 29 52 03

Principal Investigator

Samar AYACHE, Pr

STUDY CHAIR

CHU Henri Mondor

Frequently Asked Questions

Who can join the NCT07252895 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07252895 currently recruiting?

Yes, NCT07252895 is actively recruiting participants. Contact the research team at aurelie.lacroix@ottobock.com for enrollment information.

Where is the NCT07252895 trial being conducted?

This trial is being conducted at Berck, France, Créteil, France, Dijon, France, Gaillac-Toulza, France and 7 additional locations.

Who is sponsoring the NCT07252895 clinical trial?

NCT07252895 is sponsored by Otto Bock France SNC. The principal investigator is Samar AYACHE, Pr at CHU Henri Mondor. The trial plans to enroll 77 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology